Clinical usefulness of tumour markers.

L. C. Lai, S. K. Cheong, K. L. Goh, Leong Chooi Fun, C. S. Loh, J. B. Lopez, H. Nawawi, V. Sivanesaratnam, R. Subramaniam

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Tumour markers are substances related to the presence or progress of a tumour. An ideal tumour marker is (1) detectable only when malignancy is present, (2) specific for the type and site of malignancy, (3) correlates with the amount of malignant tissue present and (4) responds rapidly to a change in tumour size. At present, no tumour marker fulfills all of the above criteria. The first part of the review discusses the clinical usefulness of the commonly requested serum tumour markers, namely, prostate-specific antigen (PSA), CA 19-9, carcinoembryonic antigen (CEA), CA 125, CA 15-3, human chorionic gonadotrophin (hCG) and alpha-foetoprotein (AFP). It is hoped that this review article will decrease the abuse and misuse of these commonly requested serum tumour markers. The second part of the review discusses the clinical usefulness of catecholamines and their metabolites, calcitonin, thyroglobulin, parathyroid hormone, prolactin, adrenocorticotrophic hormone, oestrogen and progesterone receptors, p53, HER-2/c-erbB2, BRCA1 and BRCA2.

Original languageEnglish
Pages (from-to)83-105
Number of pages23
JournalThe Malaysian journal of pathology
Volume25
Issue number2
Publication statusPublished - 2003
Externally publishedYes

Fingerprint

Tumor Biomarkers
Neoplasms
CA-19-9 Antigen
Biomarkers
Thyroglobulin
Carcinoembryonic Antigen
alpha-Fetoproteins
Calcitonin
Progesterone Receptors
Chorionic Gonadotropin
Prostate-Specific Antigen
Parathyroid Hormone
Estrogen Receptors
Prolactin
Adrenocorticotropic Hormone
Catecholamines

Cite this

Lai, L. C., Cheong, S. K., Goh, K. L., Chooi Fun, L., Loh, C. S., Lopez, J. B., ... Subramaniam, R. (2003). Clinical usefulness of tumour markers. The Malaysian journal of pathology, 25(2), 83-105.

Clinical usefulness of tumour markers. / Lai, L. C.; Cheong, S. K.; Goh, K. L.; Chooi Fun, Leong; Loh, C. S.; Lopez, J. B.; Nawawi, H.; Sivanesaratnam, V.; Subramaniam, R.

In: The Malaysian journal of pathology, Vol. 25, No. 2, 2003, p. 83-105.

Research output: Contribution to journalArticle

Lai, LC, Cheong, SK, Goh, KL, Chooi Fun, L, Loh, CS, Lopez, JB, Nawawi, H, Sivanesaratnam, V & Subramaniam, R 2003, 'Clinical usefulness of tumour markers.', The Malaysian journal of pathology, vol. 25, no. 2, pp. 83-105.
Lai LC, Cheong SK, Goh KL, Chooi Fun L, Loh CS, Lopez JB et al. Clinical usefulness of tumour markers. The Malaysian journal of pathology. 2003;25(2):83-105.
Lai, L. C. ; Cheong, S. K. ; Goh, K. L. ; Chooi Fun, Leong ; Loh, C. S. ; Lopez, J. B. ; Nawawi, H. ; Sivanesaratnam, V. ; Subramaniam, R. / Clinical usefulness of tumour markers. In: The Malaysian journal of pathology. 2003 ; Vol. 25, No. 2. pp. 83-105.
@article{9f3773c703874a2f9f9b92fe6f27862a,
title = "Clinical usefulness of tumour markers.",
abstract = "Tumour markers are substances related to the presence or progress of a tumour. An ideal tumour marker is (1) detectable only when malignancy is present, (2) specific for the type and site of malignancy, (3) correlates with the amount of malignant tissue present and (4) responds rapidly to a change in tumour size. At present, no tumour marker fulfills all of the above criteria. The first part of the review discusses the clinical usefulness of the commonly requested serum tumour markers, namely, prostate-specific antigen (PSA), CA 19-9, carcinoembryonic antigen (CEA), CA 125, CA 15-3, human chorionic gonadotrophin (hCG) and alpha-foetoprotein (AFP). It is hoped that this review article will decrease the abuse and misuse of these commonly requested serum tumour markers. The second part of the review discusses the clinical usefulness of catecholamines and their metabolites, calcitonin, thyroglobulin, parathyroid hormone, prolactin, adrenocorticotrophic hormone, oestrogen and progesterone receptors, p53, HER-2/c-erbB2, BRCA1 and BRCA2.",
author = "Lai, {L. C.} and Cheong, {S. K.} and Goh, {K. L.} and {Chooi Fun}, Leong and Loh, {C. S.} and Lopez, {J. B.} and H. Nawawi and V. Sivanesaratnam and R. Subramaniam",
year = "2003",
language = "English",
volume = "25",
pages = "83--105",
journal = "Malaysian Journal of Pathology",
issn = "0126-8635",
publisher = "Malaysian Society of Pathologists",
number = "2",

}

TY - JOUR

T1 - Clinical usefulness of tumour markers.

AU - Lai, L. C.

AU - Cheong, S. K.

AU - Goh, K. L.

AU - Chooi Fun, Leong

AU - Loh, C. S.

AU - Lopez, J. B.

AU - Nawawi, H.

AU - Sivanesaratnam, V.

AU - Subramaniam, R.

PY - 2003

Y1 - 2003

N2 - Tumour markers are substances related to the presence or progress of a tumour. An ideal tumour marker is (1) detectable only when malignancy is present, (2) specific for the type and site of malignancy, (3) correlates with the amount of malignant tissue present and (4) responds rapidly to a change in tumour size. At present, no tumour marker fulfills all of the above criteria. The first part of the review discusses the clinical usefulness of the commonly requested serum tumour markers, namely, prostate-specific antigen (PSA), CA 19-9, carcinoembryonic antigen (CEA), CA 125, CA 15-3, human chorionic gonadotrophin (hCG) and alpha-foetoprotein (AFP). It is hoped that this review article will decrease the abuse and misuse of these commonly requested serum tumour markers. The second part of the review discusses the clinical usefulness of catecholamines and their metabolites, calcitonin, thyroglobulin, parathyroid hormone, prolactin, adrenocorticotrophic hormone, oestrogen and progesterone receptors, p53, HER-2/c-erbB2, BRCA1 and BRCA2.

AB - Tumour markers are substances related to the presence or progress of a tumour. An ideal tumour marker is (1) detectable only when malignancy is present, (2) specific for the type and site of malignancy, (3) correlates with the amount of malignant tissue present and (4) responds rapidly to a change in tumour size. At present, no tumour marker fulfills all of the above criteria. The first part of the review discusses the clinical usefulness of the commonly requested serum tumour markers, namely, prostate-specific antigen (PSA), CA 19-9, carcinoembryonic antigen (CEA), CA 125, CA 15-3, human chorionic gonadotrophin (hCG) and alpha-foetoprotein (AFP). It is hoped that this review article will decrease the abuse and misuse of these commonly requested serum tumour markers. The second part of the review discusses the clinical usefulness of catecholamines and their metabolites, calcitonin, thyroglobulin, parathyroid hormone, prolactin, adrenocorticotrophic hormone, oestrogen and progesterone receptors, p53, HER-2/c-erbB2, BRCA1 and BRCA2.

UR - http://www.scopus.com/inward/record.url?scp=27144516832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144516832&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 83

EP - 105

JO - Malaysian Journal of Pathology

JF - Malaysian Journal of Pathology

SN - 0126-8635

IS - 2

ER -